Health Care & Insurance  February 14, 2017

MiRagen raises $40.7 million, goes public with Signal Genetics merger

BOULDER — Clinical-stage biopharmaceutical company MiRagen Therapeutics Inc. has completed its merger with a publicly traded California company, raising $40.7 million in private equity financing just prior to the deal. MiRagen begins trading Tuesday on the Nasdaq exchange under the ticker symbol “MGEN.”

William Marshall

The Boulder-based company reported the private funding in a Regulation D filing with the U.S. Securities and Exchange Commission, Feb. 13.

The new equity financing came from current and new miRagen investors, including Fidelity Management and Research Co., Brace Pharma…

Christopher Wood
Christopher Wood is editor and publisher of BizWest, a regional business journal covering Boulder, Broomfield, Larimer and Weld counties. Wood co-founded the Northern Colorado Business Report in 1995 and served as publisher of the Boulder County Business Report until the two publications were merged to form BizWest in 2014. From 1990 to 1995, Wood served as reporter and managing editor of the Denver Business Journal. He is a Marine Corps veteran and a graduate of the University of Colorado Boulder. He has won numerous awards from the Colorado Press Association, Society of Professional Journalists and the Alliance of Area Business Publishers.
Sign up for BizWest Daily Alerts
Closing in 8 seconds...